The issuance of patent #US 8,697,055 B2 protects the use of all Bacillus coagulans probiotic strains, including GanedenBC30 in coffee, tea and cereal applications.
“Our patent attorneys at Mintz Levin continue to provide superior legal counsel that strengthens our market position,” said David Keller, Ganeden Biotech VP of scientific operations.
“This patent goes a long way toward supporting our partners in their quest to launch new brands and revolutionise existing ones,” said Andy Lefkowitz, CEO of Ganeden Biotech. “When combined with the FDA’s No Objection letter on GRAS (safety), 17 studies published in peer reviewed journals, over 100 patents issued around the world and the pending issuance of the first monograph by the USP, we have again demonstrated our commitment to science-based probiotic innovation.”
Source: Ganeden Biotech
© FoodBev Media Ltd 2024